Renovaro Inc. (2Q5.SG)
| Previous close | 1.3660 |
| Open | 1.3600 |
| Bid | 1.3640 x 0 |
| Ask | 1.4300 x 0 |
| Day's range | 1.3600 - 1.3600 |
| 52-week range | 0.3600 - 4.8400 |
| Volume | |
| Avg. volume | 16 |
| Market cap | 199.966M |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against
- GlobeNewswire
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-a
- GlobeNewswire
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies. Professor Kazemier is the Clinical Dir
